Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-01

Clinical Trial Update: UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis [NA]

View source ↗

Summary

This clinical trial update describes using UVB-311nm phototherapy after an initial slow response to adalimumab in psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Humira (adalimumab)

Snippet

Sponsor: Medical University of Graz | Conditions: Psoriasis | NA | Status: UNKNOWN